AI Summary
We reviewed 6 live results for tocilizumab and narrowed them down to the 3 options that look most worth comparing first.
The strongest themes across this short list are Medicine and Rheumatology.
Comparison Table
Recommended
Tocilizumab
Source: Samitivej Hospital
Description
An IL-6 inhibitor biologic DMARD used for rheumatoid arthritis and systemic juvenile idiopathic arthritis. It is available as an 80 mg/4 ml sterile solution and may require prior authorization for reimbursement in certain Thai health schemes.
Best for
IL-6 inhibitor therapy, juvenile idiopathic arthritis, advanced RA treatment and specialized biologic access
View Details
Rating
Tofidence
Source: Biogen
Description
Tofidence is a tocilizumab biosimilar developed for intravenous administration. It is FDA-approved for indications including Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). As a biosimilar, it aims to provide a high-quality, clinical equivalent to the originator product to improve patient access to biologic therapy.
Best for
Cost-effective biologic therapy, IV infusion therapy, Rheumatoid arthritis patients and US market access
View Details
Rating
Actemra Intravenous (IV) Infusion
Source: Roche
Description
Actemra is an Interleukin-6 (IL-6) receptor antagonist containing the active ingredient tocilizumab. This intravenous formulation is used for treating moderate to severe active Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). In Thailand, it is available in 80 mg, 200 mg, and 400 mg vials (20 mg/mL), distributed through DKSH. It is a critical biologic therapy for controlling systemic inflammation and joint damage.
Best for
Rheumatoid arthritis management, Juvenile idiopathic arthritis, Hospital-based IV treatment and Thai local access
View Details
Rating
| Compare | Tocilizumab | Tofidence | Actemra Intravenous (IV) Infusion |
|---|---|---|---|
| Source | Samitivej Hospital | Biogen | Roche |
| Description | An IL-6 inhibitor biologic DMARD used for rheumatoid arthritis and systemic juvenile idiopathic arthritis. It is available as an 80 mg/4 ml sterile solution and may require prior authorization for reimbursement in certain Thai health schemes. | Tofidence is a tocilizumab biosimilar developed for intravenous administration. It is FDA-approved for indications including Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). As a biosimilar, it aims to provide a high-quality, clinical equivalent to the originator product to improve patient access to biologic therapy. | Actemra is an Interleukin-6 (IL-6) receptor antagonist containing the active ingredient tocilizumab. This intravenous formulation is used for treating moderate to severe active Rheumatoid Arthritis (RA), Polyarticular Juvenile Idiopathic Arthritis (pJIA), and Systemic Juvenile Idiopathic Arthritis (sJIA). In Thailand, it is available in 80 mg, 200 mg, and 400 mg vials (20 mg/mL), distributed through DKSH. It is a critical biologic therapy for controlling systemic inflammation and joint damage. |
| Best for | IL-6 inhibitor therapy, juvenile idiopathic arthritis, advanced RA treatment and specialized biologic access | Cost-effective biologic therapy, IV infusion therapy, Rheumatoid arthritis patients and US market access | Rheumatoid arthritis management, Juvenile idiopathic arthritis, Hospital-based IV treatment and Thai local access |
| Tags | |||
| Action | View Details | View Details | View Details |
| Rating |
AI Recommendation
If you want the most balanced option to start with, I recommend:
"Tocilizumab from Samitivej Hospital."
I picked this because A specialized biologic therapy suitable for adult RA and systemic juvenile idiopathic arthritis cases.
Share this search
Related Finds